Saturday 17 October 2026
Export TMDX’s income statement to Excel — free account
TransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024. In the quarter to June 2026, revenue grew 20.7%, EPS fell 59.2%, free cash flow fell 87.6% and total debt rose 68.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
70.78
5.74
−7.50%
Follow TMDX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
15.03 | 19.76 | 21.80 | 41.56 |
+8 more quarters Free account |
P/S ratio |
3.44 | 5.38 | 6.83 | 6.76 | |
P/FCF ratio |
29.06 | 22.58 | 30.96 | 31.72 | |
P/Operating CF |
132.69 | 139.33 | 119.82 | 55.01 | |
P/B ratio |
4.43 | 6.92 | 8.74 | 10.78 | |
Price to Tangible BV |
4.53 | 7.08 | 9.00 | 11.20 | |
EV/Sales |
4.02 | 6.00 | 6.87 | 6.84 | |
EV/EBITDA |
22.76 | 29.94 | 30.64 | 31.91 | |
EV/Operating CF |
18.40 | 17.32 | 21.57 | 21.76 | |
EV/FCF |
33.98 | 25.19 | 31.14 | 32.10 | |
Quick Ratio |
5.87 | 6.01 | 6.41 | 6.86 | |
Current Ratio |
6.63 | 6.74 | 7.14 | 7.69 | |
Net Debt/EBITDA |
11.45 | 15.71 | 0.84 | 1.51 | |
Debt/Assets |
58.84% | 59.73% | 47.96% | 54.09% | |
Debt/Equity |
1.66 | 1.73 | 1.08 | 1.44 | |
Asset Turnover |
0.57 | 0.56 | 0.65 | 0.65 | |
Operating CF/Net income |
1.18 | 3.35 | 0.33 | 2.86 | |
Capex/Depreciation |
(0.69) | (3.09) | (2.08) | (1.11) | |
Interest Coverage |
3.29 | 1.85 | 6.34 | 6.67 | |
Research and Development Expense of Revenue |
16.65% | 14.30% | 12.88% | 10.61% | |
Selling, General and Administrative Expense of Revenue |
30.45% | 36.21% | 32.00% | 31.99% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
4.53% | 5.72% | 5.84% | 6.35% | |
Graham Net Nets |
(0.13) | (0.09) | 0.01 | 0.01 | |
Graham Number |
38.60 | 40.32 | 41.80 | 25.15 | |
Earnings Yield |
6.65% | 5.06% | 4.59% | 2.41% | |
Free Cash Flow Yield |
3.44% | 4.43% | 3.23% | 3.15% | |
Revenue per Share |
5.49 | 5.06 | 4.73 | 4.22 | |
Operating CF per Share |
0.50 | 0.71 | 1.02 | 2.04 | |
Capex per Share |
(0.21) | (1.07) | (0.46) | (0.22) | |
Free Cash Flow per Share |
0.30 | (0.35) | 0.56 | 1.82 | |
Cash per Share |
13.67 | 13.43 | 14.37 | 13.67 | |
Shareholders Equity per Share |
14.98 | 14.37 | 13.92 | 10.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.98 | 14.37 | 13.92 | 10.41 | |
Free Cash Flow |
10.22 | (12.12) | 19.00 | 61.95 | |
Working Capital |
552.84 | 527.36 | 548.48 | 533.28 | |
Capital Expenditures |
(7.09) | (36.66) | (15.51) | (7.62) | |
Net Current Asset Value |
(295.22) | (321.53) | 42.51 | 22.16 | |
EV/EBIT |
32.91 | 40.38 | 38.31 | 40.36 | |
Capex to Sales |
0.04 | 0.21 | 0.10 | 0.05 | |
Price to Operating Income |
28.15 | 36.19 | 38.08 | 39.89 | |
| Other line items | |||||
Average Receivables |
104.49 | 116.38 | 91.00 | 85.42 | |
Average Payables |
11.22 | 10.87 | 10.32 | 12.65 | |
Average Inventory |
46.50 | 46.64 | 47.72 | 48.33 | |
Average Assets |
1,177.46 | 1,136.18 | 936.22 | 865.80 | |
Average Common Equity |
418.08 | 380.16 | 350.85 | 282.56 |
Columns are period end dates